RGC - Regencell Bioscience Holdings Limited -  [ ]

Ticker Details
Regencell Bioscience Holdings Limited
IPO Date: July 16, 2021
Sector: Healthcare
Industry: Drug Manufacturers
Market Cap: $12.76B
Activated in VL: True
Average Daily Range
Avg Daily Range: $2.99 | 6.63%
Avg Daily Range (30 D): $1.08 | 3.75%
Avg Daily Range (90 D): $1.58 | 5.67%
Institutional Daily Volume
Avg Daily Volume: .19M
Avg Daily Volume (30 D): .09M
Avg Daily Volume (90 D): .18M
Trade Size
Avg Trade Size (Sh.): 67
Avg Trade Size (Sh.) (30 D): 64
Avg Trade Size (Sh.) (90 D): 61
Institutional Trades
Total Institutional Trades: 69
Avg Institutional Trade: $.93M
Avg Institutional Trade (30 D): $1.61M
Avg Institutional Trade (90 D): $.99M
Avg Institutional Trade Volume: .26M
Avg Institutional Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $.83M
Avg Closing Trade (30 D): $1.61M
Avg Closing Trade (90 D): $1.18M
Avg Closing Volume: 79.32K
 
News
May 25, 2026 @ 2:59 AM
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourage...
Source: Rosen Law Firm
May 20, 2026 @ 12:00 PM
Lead Plaintiff Deadlines in Shareholder Class Acti...
Source: Holzer & Holzer, Llc
May 19, 2026 @ 12:12 AM
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regenc...
Source: Rosen Law Firm
May 14, 2026 @ 6:40 PM
DEADLINE ALERT for RGC, SES, FSK: Law Offices of H...
Source: Law Offices Of Howard G. Smith
May 13, 2026 @ 4:00 PM
Bronstein, Gewirtz & Grossman LLC Urges Regencell ...
Source: Bronstein, Gewirtz & Grossman Llc
Financials
  TTM Q4 2017 FY 2017
Basic EPS $.72 $.19 $.72
Diluted EPS $.72 $.19 $.72
Revenue $3.16B $861.6M $3.16B
Gross Profit
Net Income / Loss $112.3M $28.9M $112.3M
Operating Income / Loss $271.7M $90.7M $271.7M
Cost of Revenue
Net Cash Flow $-17.7M $39.3M $-17.7M
PE Ratio    
Splits
Jun 16, 2025 38:1